Aspire Biopharma Holdings, Inc. (ASBP)
NASDAQ: ASBP · Real-Time Price · USD
0.4301
-0.1723 (-28.60%)
At close: May 30, 2025, 4:00 PM
0.4156
-0.0145 (-3.37%)
After-hours: May 30, 2025, 7:59 PM EDT

Company Description

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, engages in development and marketing of disruptive technology for novel sublingual delivery mechanisms in the United States.

The company offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management.

It also develops formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product.

In addition, the company develops formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement.

Aspire Biopharma Holdings, Inc. was founded in 2021 and is headquartered in Humacao, Puerto Rico.

Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings logo
Country United States
Founded 2021
Industry Biotechnology
Sector Healthcare
CEO Kraig Higginson

Contact Details

Address:
194 Candelaro Drive, Suite 233
Humacao, PR 00791
United States
Phone 415 592 7399
Website aspirebiolabs.com

Stock Details

Ticker Symbol ASBP
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001847345
CUSIP Number 738920107
ISIN Number US7389201077

Key Executives

Name Position
Kraig T. Higginson President, Chief Executive Officer and Chairman of Board
Ernest J. Scheidemann Jr. Chief Financial Officer
Stephen E. Quesenberry General Counsel and Corporate Secretary